QQQ   354.92 (-1.75%)
AAPL   172.40 (-0.78%)
MSFT   313.39 (-2.61%)
META   300.94 (-1.92%)
GOOGL   132.43 (-1.30%)
AMZN   124.72 (-3.66%)
TSLA   246.53 (-2.02%)
NVDA   435.17 (-2.82%)
NIO   8.61 (-2.05%)
BABA   84.57 (-2.27%)
AMD   100.08 (-3.09%)
T   14.79 (+0.82%)
F   12.07 (-1.95%)
MU   67.83 (-0.19%)
CGC   0.68 (-6.82%)
GE   107.77 (-0.94%)
DIS   79.54 (-2.61%)
AMC   7.86 (-3.56%)
PFE   33.90 (-0.12%)
PYPL   57.30 (-2.15%)
NFLX   376.75 (-0.94%)
QQQ   354.92 (-1.75%)
AAPL   172.40 (-0.78%)
MSFT   313.39 (-2.61%)
META   300.94 (-1.92%)
GOOGL   132.43 (-1.30%)
AMZN   124.72 (-3.66%)
TSLA   246.53 (-2.02%)
NVDA   435.17 (-2.82%)
NIO   8.61 (-2.05%)
BABA   84.57 (-2.27%)
AMD   100.08 (-3.09%)
T   14.79 (+0.82%)
F   12.07 (-1.95%)
MU   67.83 (-0.19%)
CGC   0.68 (-6.82%)
GE   107.77 (-0.94%)
DIS   79.54 (-2.61%)
AMC   7.86 (-3.56%)
PFE   33.90 (-0.12%)
PYPL   57.30 (-2.15%)
NFLX   376.75 (-0.94%)
QQQ   354.92 (-1.75%)
AAPL   172.40 (-0.78%)
MSFT   313.39 (-2.61%)
META   300.94 (-1.92%)
GOOGL   132.43 (-1.30%)
AMZN   124.72 (-3.66%)
TSLA   246.53 (-2.02%)
NVDA   435.17 (-2.82%)
NIO   8.61 (-2.05%)
BABA   84.57 (-2.27%)
AMD   100.08 (-3.09%)
T   14.79 (+0.82%)
F   12.07 (-1.95%)
MU   67.83 (-0.19%)
CGC   0.68 (-6.82%)
GE   107.77 (-0.94%)
DIS   79.54 (-2.61%)
AMC   7.86 (-3.56%)
PFE   33.90 (-0.12%)
PYPL   57.30 (-2.15%)
NFLX   376.75 (-0.94%)
QQQ   354.92 (-1.75%)
AAPL   172.40 (-0.78%)
MSFT   313.39 (-2.61%)
META   300.94 (-1.92%)
GOOGL   132.43 (-1.30%)
AMZN   124.72 (-3.66%)
TSLA   246.53 (-2.02%)
NVDA   435.17 (-2.82%)
NIO   8.61 (-2.05%)
BABA   84.57 (-2.27%)
AMD   100.08 (-3.09%)
T   14.79 (+0.82%)
F   12.07 (-1.95%)
MU   67.83 (-0.19%)
CGC   0.68 (-6.82%)
GE   107.77 (-0.94%)
DIS   79.54 (-2.61%)
AMC   7.86 (-3.56%)
PFE   33.90 (-0.12%)
PYPL   57.30 (-2.15%)
NFLX   376.75 (-0.94%)
Lowest-Rated StocksLowest-Rated
NASDAQ:MRNA

Moderna (MRNA) Stock Forecast, Price & News

$103.08
-0.23 (-0.22%)
(As of 10/3/2023 ET)
Compare
Today's Range
$100.92
▼
$103.68
50-Day Range
$96.41
▼
$121.87
52-Week Range
$95.02
▼
$217.25
Volume
2.42 million shs
Average Volume
3.59 million shs
Market Capitalization
$39.23 billion
P/E Ratio
38.04
Dividend Yield
N/A
Price Target
$155.52
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

Moderna MarketRank™ Forecast

Analyst Rating
Hold
2.17 Rating Score
Upside/​Downside
50.9% Upside
$155.52 Price Target
Short Interest
Bearish
5.49% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.71
Upright™ Environmental Score
News Sentiment
0.85mentions of Moderna in the last 14 days
Based on 28 Articles This Week
Insider Trading
Selling Shares
$24.60 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($4.32) to ($5.55) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.64 out of 5 stars

Medical Sector

116th out of 976 stocks

Biological Products, Except Diagnostic Industry

12th out of 150 stocks

See Top Rated MarketRank™ Stocks Here

MRNA stock logo

About Moderna (NASDAQ:MRNA) Stock

Moderna Inc., founded in 2010, is a biotechnology company focused on creating transformative medicines to combat viruses and other diseases. The company utilizes messenger ribonucleic acid (mRNA) technology, which transports information from a living creature's DNA to other parts of the body. The company has experienced rapid growth due to its innovative mRNA technologies, especially as the U.S. authorized the COVID-19 vaccine developed by Moderna Inc. for human use in December 2020.

Moderna Inc. operates in multiple therapeutic areas, including infectious diseases, immuno-oncology, rare diseases, autoimmune diseases and cardiovascular diseases. Its product pipeline includes prophylactic vaccines, localized regenerative therapeutics, cancer vaccines, systemic secreted therapeutics, intratumoral immuno-oncology and systemic intracellular therapeutics. The company is also developing vaccines and therapeutics for other infectious diseases, such as influenza, hMPV+PIV3, respiratory syncytial virus, endemic HCoV, cytomegalovirus, human immunodeficiency virus, herpes simplex virus, Epstein-Barr virus and varicella-zoster virus.

Moderna Inc. is actively working to develop a range of pharmaceutical solutions and vaccines and to increase its strategic alliances. The company has seen success in its innovative mRNA technologies, and its growing partnerships have given them an edge over its competitors. 

As the company continues to advance its technologies and expand its strategic alliances, Moderna Inc. is proving to be a reliable source of transformative medicines to combat viruses and other diseases.

Moderna Inc. has formed strategic partnerships with a variety of pharmaceutical companies, including AstraZeneca PLC, Merck & Co. Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics Inc., Metagenomi Inc., the Defense Advanced Research Projects Agency, Biomedical Advanced Research and Development Authority, Institute for Life Changing Medicines and the Bill & Melinda Gates Foundation. Furthermore, the company has a collaboration and license agreement with Chiesi Farmaceutici S.P.A. 

MRNA Price History

MRNA Stock News Headlines

October 3, 2023 | yahoo.com
Nobel Prize in medicine goes to scientists who paved the way for COVID-19 mRNA vaccines
October 3, 2023 | benzinga.com
Moderna Unusual Options Activity For October 03
October 3, 2023 | UNKNOWN (Ad)
A Bio-Tech Stock That Has Been Growing Like Crazy!
Recent News for This One Bio-Tech Has Us All Getting Excited. Sign Up today And Learn More
October 3, 2023 | msn.com
Researcher Demoted By University Of Pennsylvania Wins Nobel Prize For mRNA Discoveries—And Some Academics Urge Penn To Apologize
October 3, 2023 | msn.com
What is mRNA Vaccine? How Does it Help to Fight Against COVID-19?
October 2, 2023 | news.yahoo.com
Nobel Prize in medicine won by two scientists for ‘groundbreaking findings’ on mRNA Covid-19 vaccines
October 2, 2023 | msn.com
Nobel medicine prize: How two scientists modified mRNA for vaccine breakthrough
October 2, 2023 | time.com
Nobel Prize Awarded to mRNA Pioneers Who Paved the Way for COVID-19 Vaccines
October 3, 2023 | UNKNOWN (Ad)
A Bio-Tech Stock That Has Been Growing Like Crazy!
Recent News for This One Bio-Tech Has Us All Getting Excited. Sign Up today And Learn More
October 2, 2023 | washingtonpost.com
mRNA Proved Magic in Covid Vaccines. What Else Can It Do?
October 2, 2023 | finance.yahoo.com
MRNA Pioneers Find Redemption in Nobel Prize
October 2, 2023 | reuters.com
BRIEF-Biontech Applauds Nobel Prize Winners Kariko And Weissman
October 2, 2023 | uk.finance.yahoo.com
Scientists Behind Pfizer and Moderna mRNA Vaccines Win Nobel
October 2, 2023 | msn.com
Nobel Prize Honors Scientists Behind mRNA Vaccines Against Covid-19
October 2, 2023 | yahoo.com
Two Penn scientists awarded Nobel Prize in Medicine for work with mRNA, COVID-19 vaccines
October 2, 2023 | msn.com
Nobel Prize Goes to Duo for mRNA Vaccine Development
October 2, 2023 | msn.com
Scientists Win Nobel Prize for mRNA Breakthrough Used to Create Covid-19 Vaccine
October 2, 2023 | finance.yahoo.com
Scientists Who Pioneered mRNA Vaccine Technology Win Nobel Prize in Medicine
October 2, 2023 | finance.yahoo.com
Years of research laid the groundwork for speedy COVID-19 shots
October 2, 2023 | news.yahoo.com
Nobel Prize in medicine goes to Katalin Karikó and Drew Weissman for work on mRNA Covid-19 vaccines
October 2, 2023 | msn.com
Nobel Prize Given To Researchers Behind MRNA Tech In Covid Vaccines
October 2, 2023 | msn.com
Katalin Kariko, scientific maverick who paved way for mRNA vaccines
October 2, 2023 | news.yahoo.com
Nobel prize goes to mRNA Covid vaccine researchers
October 2, 2023 | msn.com
Scientists behind mRNA vaccines win Nobel Prize in Medicine
October 1, 2023 | americanbankingnews.com
Noubar Afeyan Sells 10,000 Shares of Moderna, Inc. (NASDAQ:MRNA) Stock
September 29, 2023 | finance.yahoo.com
Moderna Recommends Shareholders Reject Amended “Mini-Tender” Offer by TRC Capital Investment Corporation
September 26, 2023 | reuters.com
EU in talks with Moderna over new deal for COVID vaccines - FT
See More Headlines
Receive MRNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Moderna and its competitors with MarketBeat's FREE daily newsletter.

MRNA Company Calendar

Last Earnings
8/03/2023
Today
10/03/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MRNA
CUSIP
N/A
CIK
1682852
Web
www.modernatx.com
Phone
(617) 714-6500
Fax
N/A
Employees
3,900
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$155.52
High Stock Price Forecast
$296.00
Low Stock Price Forecast
$93.00
Forecasted Upside/Downside
+51.6%
Consensus Rating
Hold
Rating Score (0-4)
2.17
Research Coverage
18 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$2.71
Trailing P/E Ratio
37.85
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$8.36 billion
Net Margins
11.33%
Pretax Margin
7.68%
Return on Equity
6.62%
Return on Assets
4.93%

Debt

Debt-to-Equity Ratio
0.05
Current Ratio
3.39
Quick Ratio
3.16

Sales & Book Value

Annual Sales
$19.26 billion
Price / Sales
2.03
Cash Flow
$22.59 per share
Price / Cash Flow
4.54
Book Value
$49.78 per share
Price / Book
2.06

Miscellaneous

Outstanding Shares
380,590,000
Free Float
320,840,000
Market Cap
$39.04 billion
Optionable
Optionable
Beta
1.65

Social Links

Investing Strategies To Help Grow Your Retirement Income Cover
Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Mr. Stephane BancelMr. Stephane Bancel (Age 50)
    CEO & Director
    Comp: $4.97M
  • Dr. Stephen Hoge M.D. (Age 47)
    Pres
    Comp: $2.41M
  • Mr. James M. Mock (Age 46)
    Chief Financial Officer
    Comp: $1.49M
  • Ms. Arpa Garay (Age 44)
    Chief Commercial Officer
    Comp: $2.67M
  • Dr. Jerh Collins Ph.D. (Age 57)
    Chief Technical Operations & Quality Officer
  • Dr. Melissa J. Moore Ph.D.
    Chief Scientific Officer & Member of Scientific Advisory Board
  • Mr. Brad Miller (Age 50)
    Chief Information Officer
  • Ms. Lavina Talukdar CFA
    Sr. VP & Head of Investor Relations
  • Ms. Shannon Thyme KlingerMs. Shannon Thyme Klinger (Age 52)
    Chief Legal Officer & Corp. Sec.
  • Colleen Hussey
    Sr. Director of Corp. Communications

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













MRNA Stock - Frequently Asked Questions

Should I buy or sell Moderna stock right now?

18 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Moderna in the last twelve months. There are currently 3 sell ratings, 9 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" MRNA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MRNA, but not buy additional shares or sell existing shares.
View MRNA analyst ratings or view top-rated stocks.

What is Moderna's stock price forecast for 2023?

18 brokers have issued 12-month target prices for Moderna's stock. Their MRNA share price forecasts range from $93.00 to $296.00. On average, they anticipate the company's share price to reach $155.52 in the next year. This suggests a possible upside of 51.6% from the stock's current price.
View analysts price targets for MRNA or view top-rated stocks among Wall Street analysts.

How have MRNA shares performed in 2023?

Moderna's stock was trading at $179.62 at the start of the year. Since then, MRNA stock has decreased by 42.9% and is now trading at $102.58.
View the best growth stocks for 2023 here.

When is Moderna's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our MRNA earnings forecast.

How were Moderna's earnings last quarter?

Moderna, Inc. (NASDAQ:MRNA) posted its quarterly earnings data on Thursday, August, 3rd. The company reported ($3.62) EPS for the quarter, topping the consensus estimate of ($3.84) by $0.22. The business had revenue of $344 million for the quarter, compared to analyst estimates of $307.67 million. Moderna had a net margin of 11.33% and a trailing twelve-month return on equity of 6.62%. Moderna's revenue was down 92.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $5.24 EPS.

What ETFs hold Moderna's stock?

ETFs with the largest weight of Moderna (NASDAQ:MRNA) stock in their portfolio include Morningstar US Small Growth (MSGR), ETFMG Treatments Testing and Advancements ETF (GERM), VanEck Biotech ETF (BBH), Invesco Nasdaq Biotechnology ETF (IBBQ), iShares Biotechnology ETF (IBB), iShares Genomics Immunology and Healthcare ETF (IDNA), ProShares Nanotechnology ETF (TINY) and iShares U.S. Tech Breakthrough Multisector ETF (TECB).

What is Stéphane Bancel's approval rating as Moderna's CEO?

57 employees have rated Moderna Chief Executive Officer Stéphane Bancel on Glassdoor.com. Stéphane Bancel has an approval rating of 92% among the company's employees. This puts Stéphane Bancel in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Moderna own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Moderna investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Pfizer (PFE), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Novavax (NVAX), Johnson & Johnson (JNJ), Alibaba Group (BABA) and Zoom Video Communications (ZM).

When did Moderna IPO?

(MRNA) raised $499 million in an initial public offering (IPO) on Friday, December 7th 2018. The company issued 21,700,000 shares at a price of $22.00-$24.00 per share. Morgan Stanley, Goldman Sachs and J.P. Morgan acted as the underwriters for the IPO and BofA Merrill Lynch, Barclays, Piper Jaffray, Bryan, Garnier, Oddo BHF, Oppenheimer, Needham and Chardan were co-managers.

What is Moderna's stock symbol?

Moderna trades on the NASDAQ under the ticker symbol "MRNA."

How do I buy shares of Moderna?

Shares of MRNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Moderna's stock price today?

One share of MRNA stock can currently be purchased for approximately $102.58.

How much money does Moderna make?

Moderna (NASDAQ:MRNA) has a market capitalization of $39.04 billion and generates $19.26 billion in revenue each year. The company earns $8.36 billion in net income (profit) each year or $2.71 on an earnings per share basis.

How many employees does Moderna have?

The company employs 3,900 workers across the globe.

How can I contact Moderna?

Moderna's mailing address is 200 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The official website for the company is www.modernatx.com. The company can be reached via phone at (617) 714-6500 or via email at ir@modernatx.com.

This page (NASDAQ:MRNA) was last updated on 10/3/2023 by MarketBeat.com Staff

My Account -